Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: Implications for combination therapy for melanoma brain metastases

Drug Metabolism and Disposition

Volumn 42, Issue 8, 2014, Pages 1292-1300

  Vaidhyanathan, Shruthi ^a   Mittapalli, Rajendar K ^a   Sarkaria, Jann N ^b   Elmquist, William F ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; COLCHICINE; DABRAFENIB; DIGOXIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MULTIDRUG RESISTANCE PROTEIN; PRAZOSIN; TRAMETINIB; VEMURAFENIB; ABC TRANSPORTER; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; CONTROLLED STUDY; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEQUENCE HOMOLOGY; TRANSGENIC MOUSE; TREATMENT OUTCOME; VIRUS ONCOGENE; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; DOG; KNOCKOUT MOUSE; MDCK CELL LINE; METABOLISM; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; PLASMA; PROCEDURES; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; AREA UNDER CURVE; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DOGS; MADIN DARBY CANINE KIDNEY CELLS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MELANOMA; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; P-GLYCOPROTEINS; PLASMA; PROTEIN KINASE INHIBITORS; PYRIDONES; PYRIMIDINONES;

EID: 84904191651     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.058339     Document Type: Article

References (31)

1. Agarwal S, Hartz AM, Elmquist WF, and Bauer B (2011) Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des 17:2793-2802.
2. Agarwal S, Uchida Y, Mittapalli RK, Sane R, Terasaki T, and Elmquist WF (2012) Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. Drug Metab Dispos 40:1164-1169.
3. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, and Hawkins M, et al. (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116. (Pubitemid 29318842)
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, and Maio M, et al.; BRIM-3 Study Group (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516.
5. Comis RL (1976) DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Rep 60:165-176.
6. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, and Bottomley W, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954. (Pubitemid 34716871)
7. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, and Bedikian A (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117:1687-1696.
8. Enokizono J, Kusuhara H, Ose A, Schinkel AH, and Sugiyama Y (2008) Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metab Dispos 36:995-1002. (Pubitemid 351717455)
9. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, and Pavlick AC, et al. (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379: 1893-1901.
10. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, Harman R, Petersen- Schaefer K, Zacest AC, and Besser M, et al. (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22:1293-1300. (Pubitemid 41079844)
11. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, and Nolop K, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819.
12. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, and Mohr P, et al.; METRIC Study Group (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-114.
13. Garbe C, Eigentler TK, Keilholz U, Hauschild A, and Kirkwood JM (2011) Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16:5-24.
14. Gibney GT, Forsyth PA, and Sondak VK (2012) Melanoma in the brain: biology and therapeutic options. Melanoma Res 22:177-183.
15. Gowrishankar K, Snoyman S, Pupo GM, Becker TM, Kefford RF, and Rizos H (2012) Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. J Invest Dermatol 132:1850-1859.
16. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Jr, and Kaempgen E, et al. (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365.
17. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, and Barretina J, et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968-972.
18. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, and Hwu P, et al. (2013) Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 31:482-489.
19. Kim T, Kim J, and Lee MG (2010) Inhibition of mutated BRAF in melanoma. N Engl J Med 363: 2261-2262.
20. Kodaira H, Kusuhara H, Ushiki J, Fuse E, and Sugiyama Y (2010) Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther 333:788-796.
21. McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi P, Bonati A, Cervello M, Lee JT, and Steelman LS (2008) Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Curr Opin Investig Drugs 9:614-630. (Pubitemid 351777165)
22. Mittapalli RK, Vaidhyanathan S, Sane R, and Elmquist WF (2012) Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther 342:33-40.
23. Mittapalli RK, Vaidhyanathan S, Dudek AZ, and Elmquist WF (2013) Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther 344: 655-664.
24. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, and Sazegar H, et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-977.
25. Ohtsuki S and Terasaki T (2007) Contribution of carrier-mediated transport systems to the bloodbrain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res 24:1745-1758. (Pubitemid 47206624)
26. Rochet NM, Dronca RS, Kottschade LA, Chavan RN, Gorman B, Gilbertson JR, and Markovic SN (2012) Melanoma brain metastases and vemurafenib: need for further investigation. Mayo Clin Proc 87:976-981.
27. Sampson JH, Carter JH, Jr, Friedman AH, and Seigler HF (1998) Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88: 11-20. (Pubitemid 28018958)
28. Skibber JM, Soong SJ, Austin L, Balch CM, and Sawaya RE (1996) Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol 3:118-123. (Pubitemid 126729498)
29. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, and Terasaki T (2011) Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 117:333-345.
30. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, and Kee D, et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:683-695.
31. Wang T, Agarwal S, and Elmquist WF (2012) Brain distribution of cediranib is limited by active efflux at the blood-brain barrier. J Pharmacol Exp Ther 341:386-395.